Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2020-11-03 AGM Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
CEO Presentation to AGM 15 pages 1.7MB
AGM Information Classification · 95% confidence The document is titled '2020 AGM' and contains detailed information typically presented at an Annual General Meeting, including executive summaries, leadership team introductions, pipeline updates, financial highlights, and future outlook. It includes forward-looking statements, FDA approval news, cash position, and strategic plans, which are common in AGM presentations. The presence of pictures and slides further supports this being presentation material rather than a formal report like an Annual Report (10-K) or Interim Report (IR). There is no indication that this is a full financial report or audit, nor is it a transcript or legal filing. The document length and content align with AGM Information filings, which are presentations and materials shared during the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-11-03 English
Results of Meeting 2 pages 186.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is dated 4 November 2020 and is addressed to the Australian Securities Exchange. It reports the outcomes of the Annual General Meeting (AGM) of Pharmaxis Ltd held on that date. The content includes detailed voting results for various resolutions passed at the AGM, such as the Remuneration Report and re-election of directors. There is no indication that this is the full AGM presentation or materials, but rather the official announcement of the voting results. The document references ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001, which pertain to disclosure of meeting outcomes. The document length is relatively short (2691 characters), consistent with a voting results announcement rather than a full report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-11-03 English
Appendix 3G - Employee Options 13 pages 178.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of unquoted securities under an employee incentive scheme, including specifics about performance rights granted to employees. This type of filing is a regulatory announcement about capital changes, specifically the issuance of securities under an employee incentive plan. It is not a full financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail support this classification with high confidence.
2020-11-03 English
Change of Director's Interest Notice 2 pages 145.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares/options held before and after the change, nature of the change, and dates. This is a clear report of personal share transactions by a company director. The document length is 3547 characters, which is typical for such notices. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of 'Director's Dealing' (DIRS).
2020-11-03 English
Ceasing to be a substantial holder from Arix Bioscience 3 pages 241.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001 Section 671B, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding, including dates, nature of changes, consideration given, and number of securities affected. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2020-11-02 English
FDA Approves Bronchitol for US Market 3 pages 132.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 2 November 2020, detailing the FDA approval of Bronchitol for the US market, milestone payments, expected sales, and strategic implications for Pharmaxis Ltd. It includes forward-looking statements, contact information, and company background. The document is a corporate announcement about a regulatory approval and business update, not a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial analysis. The length is 8933 characters, which is relatively short and typical for a market announcement. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a call transcript or a voting result announcement. The content focuses on a significant regulatory approval and related business milestones, which fits best under Capital/Financing Update (CAP) as it discusses milestone payments and cash flow implications from the approval and licensing agreement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-11-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.